Source article

ANN ARBOR, Mich., Aug. 02, 2017 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (KBLB) (“Company”), the leading developer of spider silk based fibers, today announced that the U.S. Army awarded the optional phase of its contract with the Company valued at more than $900,000. Under this exercised option, the Company will work to design, produce, and deliver additional recombinant spider silk materials tailored for the protective needs of our Soldiers. With this additional award the total contract is now valued at more than $1.0 million.

“When I founded this Company it was with the dream that one day we would work with the US Army to produce ultra-high strength materials in support of our Warfighters,” said Company CEO and founder, Kim K. Thomson. “The Army’s exercise of its option under our agreement validates that dream. Our team is honored to be working on this noble project and we intend to provide this very important customer with the very best high strength polymers using our recombinant spider silk technology.”

“We are extremely excited to continue our work with the US Army to deliver revolutionary materials to support the Warfighter,” stated Jon Rice, COO. “Under this new phase we will be working closely with our sponsor agency to match the performance of our spider silk to their specific use cases and protective applications. I would like to thank our team for the incredible amount of effort they’ve put in to make the first phase of this project a success and express my gratitude to our sponsor for the trust and confidence they’ve placed in us to deliver the next generation of spider silk solutions. The potential uses of spider silk are nearly limitless, but one of the greatest honors is being able to apply our technology to serving those who dedicate themselves to serving and protecting all of us.”

This additional work on the contract is scheduled to last roughly 12 months and is the Company’s second US Department of Defense award.

To view the most recent edition of Kraig’s Spider Sense quarterly newsletter and/or to sign up for Company alerts, please go to www.KraigLabs.com/newsletter

About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Contact:

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
[email protected]

Source: https://finance.yahoo.com/news/u-army-exercises-contract-option-100500374.html

IMPORTANT NOTICE AND DISCLAIMER: This featured company newsletter is paid advertising not a detailed financial analysis of the Company. Next Level stocks and Access-Wall street, have been compensated to publish this newsletter as they are a shareholder as set forth below. Publisher has been covering KBLB for several years and has a contract with warrants to purchase restricted shares. We will not be trading in KBLB stock at the time of this news; publisher and its affiliates will not be selling any shares during the publication of this news. PUBLISHER only takes on clients whom it can recommend a strong buy it has never recommended a hold or sell. PUBLISHER has and will sell its shares well below its target prices. PUBLISHER does not hold any professional licenses of any kind and is not offering securities for sale. DO NOT PURCHASE SHARES OF KBLB UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT Publisher owns shares of stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration. There is no guarantee the company will reach its projections and future dilution is expected to a certain extent and will of course lower the per share price. All pink sheet and over the counter bulletin board companies are high risk investments and you should not invest unless you can afford to lose your entire investment. PUBLISHER is not a registered investment advisor or broker-dealer, this newsletter is provided as an information service only and the statements contained herein should not be construed as an offer or solicitation to buy or sell any security. An investment in companies’ trading on the OTCBB such as KBLB represents a high degree of risk, as with all investments there is a possibility of losing your entire investments. PUBLISHER makes no warranties as to the accuracy of any of the content herein and accept no liability for how readers may choose to utilize the content. Readers should perform their own due diligence, including reviewing the Company’s filings at www.sec.gov and consulting with a licensed, qualified investment professional or analyst and after reviewing the publicly available statements and other information about the companies with limited operations and no history earnings.